Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphataemia.
Three short prepubertal children with X-linked hypophosphataemia were treated with 1 IU recombinant human growth hormone (rhGH)/kg per week sc in addition to calcitriol and phosphate supplementation over a period of 3 years. Improvement of height standard deviation score (SDS) ranged from 1.0-1.7 SD based on an increase in sitting height of 1.5-2.9 SD, whereas subischial leg length improved only slightly by 0.3-0.9 SD. In all three patients, renal phosphate threshold concentration increased slightly and transient hyperparathyroidism was noted.


CONCLUSIONS
Treatment of stunted children with X-linked hypophosphataemia is effective in improving growth velocity, but appears to aggravate the pre-existent disproportionate stature of such children.
Haffner
D
D
Sektion für Pädiatrische Nephrologie, Universitäts-Kinderklinik, Heidelberg, Germany.
Wühl
E
E
Blum
W F
WF
Schaefer
F
F
Mehls
O
O
D000886:Anthropometry; D001827:Body Height / Q000187:drug effects* / Q000235:genetics; D002648:Child; D004392:Dwarfism / Q000235:genetics / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D017674:Hypophosphatemia / Q000235:genetics / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
D011994:Recombinant Proteins; D013006:Growth Hormone